Abstract
This commentary article conveys the views of the board of the Nanomedicine and Nanoscale Delivery Focus Group
of the Controlled Release Society regarding the decision of the United States National Cancer Institute (NCI) in
halting funding for the Centers of Cancer Nanotechnology Excellence (CCNEs), and the subsequent editorial articles
that broadened this discussion.
of the Controlled Release Society regarding the decision of the United States National Cancer Institute (NCI) in
halting funding for the Centers of Cancer Nanotechnology Excellence (CCNEs), and the subsequent editorial articles
that broadened this discussion.